Shanwu Ma

Shanwu Ma

Auto-generated profile, based on publicly available information

Shanwu Ma

Department of Thoracic Surgery Peking University Third Hospital Beijing China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2020 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
SMShanwu Ma
Shanwu Ma
XWXiaowei Wang
Xiaowei Wang
ZZZhenrong Zhang
Zhenrong Zhang
DLDeruo Liu
Deruo Liu
Background: Non‐small cell lung cancer (NSCLC) is the leading cause of cancer‐associated mortality worldwide of which lung adenocarcinoma (LUAD) is the most common. The identification of oncogenes and effective drug targets is the key to individualized LUAD treatment. Actin‐like protein 8 (ACTL8), a member of the cancer/testis antigen family, is associated with tumor growth and patient prognosis in various types of cancer. However, whether ACTL8 is involved in the development of LUAD remains unknown. The aim of the present study was to demonstrate the role of ACTL8 in human LUAD cells.Methods: The expression of ACTL8 in LUAD tissues and cell lines was assessed using immunohistochemistry and western blotting. Additionally, plasmids expressing ACTL8‐specific short hairpin RNAs were used to generate lentiviruses which were subsequently used to infect A549 and NCI‐H1975 human LUAD cells. Cell proliferation, migration, invasion and apoptosis, as well as cell cycle progression and the expression of protein markers of epithelial to mesenchymal transition were investigated. A549 cell tumor growth in nude mice was also examined.Results: The results showed that ACTL8 was highly expressed in A549 and NCI‐H1975 LUAD cell lines. Additionally, ACTL8‐knockdown inhibited proliferation, colony formation, cell cycle progression, migration and invasion, and increased apoptosis in both cell lines. Furthermore, in vivo experiments in nude mice revealed that ACTL8‐knockdown inhibited A549 cell tumor growth.Conclusion: These results suggest that ACTL8 serves an oncogenic role in human LUAD cells, and that ACTL8 may represent a potential therapeutic target for LUAD.Key points: Our results suggest that ACTL8 serves an oncogenic role in human LUAD cells, and that ACTL8 may represent a potential therapeutic target for LUAD.

4 March 2021 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
CLChutong Lin
Chutong Lin
FHFengling Hu
Fengling Hu
HCHongling Chu
Hongling Chu
PRPeng Ren
Peng Ren
SMShanwu Ma
Shanwu Ma
SMShaohua Ma
Shaohua Ma
Background: The role of adjuvant epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) is not clear in early‐stage nonsmall‐cell lung cancer (NSCLC) patients. This meta‐analysis aims to compare the efficacy and safety of EGFR‐TKIs as adjuvant therapy with chemotherapy or placebo in NSCLC patients harboring EGFR mutations.Patients and Methods: Pubmed, Embase, and Cochrane databases were searched for randomized controlled trials. The hazard ratio (HR) of disease‐free survival (DFS) and overall survival (OS) as well as the risk ratio (RR) of severe adverse events were merged.Results: Seven articles from five studies from 1843 records, a total of 1227 patients, were included in the analysis. The HR for DFS was 0.38 (95% confidence interval [CI] 0.22–0.63), in favor of EGFR‐TKIs. However, no significant benefit of OS was seen (HR = 0.61, 95% CI 0.31–1.22). Treatment benefit was more pronounced in patients with advanced disease stage and longer duration of medication, EGFR exon 19 deletion mutation, and treatment with third‐generation EGFR‐TKIs. Adjuvant targeted therapy may cause few adverse events compared with chemotherapy (RR = 0.28, 95% CI 0.09–0.94). The possibility of severe adverse events for the first‐generation drugs was significantly lower than for third‐generation drugs.Conclusion: In EGFR mutation‐positive patients with stage IB–IIIA NSCLC, compared with adjuvant chemotherapy or placebo, adjuvant EGFR‐TKIs should effectively improve the patient's DFS, but not effectively improve OS. Disease stage, treatment duration, mutation types, and therapeutic drugs could affect the degree of benefit. Adjuvant EGFR‐TKIs had more favorable tolerability than chemotherapy, especially with the usage of first‐generation drugs.

10 June 2026 in Thoracic Cancer
Verified
Journal Article
Open access
HHHuayu He
Huayu He
JBJie Bai
Jie Bai
JTJizheng Tang
Jizheng Tang
YNYingze Ning
Yingze Ning
WHWei He
Wei He
GQGuangliang Qiang
Guangliang Qiang
Background: With the widespread use of low‐dose computed tomography (LDCT), the detection rate of bilateral multiple pulmonary nodules (BMPNs) has increased significantly. Surgical treatment remains the main treatment for multiple pulmonary nodules (MPNs), and its therapeutic value for simultaneous BMPNs is becoming increasingly prominent. However, the safety and feasibility of synchronous bilateral surgery (SBS) remain underexplored. This study aimed to evaluate the perioperative outcomes and prognosis of patients who underwent SBS for multiple pulmonary nodules. Methods: We retrospectively analyzed the data from 108 patients who underwent synchronous bilateral resection for MPNs at Peking University Third Hospital between January 2015 and December 2025. Clinical, pathological, and perioperative data were collected. Postoperative complications were classified using the Clavien–Dindo system. Risk factors for postoperative complications were identified using a logistic regression analysis. Overall survival was estimated using the Kaplan–Meier method. Results: Among the 108 patients, 62.0% were female, and 79.6% were nonsmokers. The most common surgical combination was wedge resection combined with wedge resection (44.4%). The mean postoperative hospital stay was 6.55 ± 3.03 days. The most common complications were constipation (53.7%) and sleep disorders (51.9%), while severe complications occurred in fewer than 5% of the patients. No 30‐day mortality or unplanned secondary surgery was observed. Prolonged chest tube drainage (> 3 days) was identified as an independent risk factor for grade ≥ 2 complications ( p < 0.05). The 5‐year overall survival rate was 92.3%. Conclusions: SBS for MPNs is safe and feasible in selected patients, with acceptable perioperative outcomes and favorable survival.

7 April 2026 in Thoracic Cancer
Verified
Journal Article
Open access
QDQunzhe Ding
Qunzhe Ding
CLChutong Lin
Chutong Lin
YLYatsu Lam
Yatsu Lam
FGFuxin Guo
Fuxin Guo
SMShanwu Ma
Shanwu Ma
GQGuangliang Qiang
Guangliang Qiang
Background: Stage IB lung squamous‐cell carcinoma (LSCC) lacks individualized survival prediction tools. There's debate on adjuvant chemotherapy's benefit. This study aimed to develop an interpretable machine‐learning model for stage IB LSCC survival prediction and re‐evaluate postoperative chemotherapy's added value. Methods: A total of 6445 patients with stage IB LSCC diagnosed between 2000 and 2015 were extracted from the SEER database. Patients from 2000 to 2014 ( n = 5740) were split 7:3 into training and internal validation cohorts, while those from 2015 ( n = 705) served as the external validation cohort. Six machine‐learning algorithms (including logistic regression and gradient‐boosting models) were trained to predict 1‐, 3‐, and 5‐year overall survival (OS) with hyperparameter optimization via 10‐fold cross‐validation. SHAP analysis ensured model interpretability, and 1:1 nearest‐neighbor propensity‐score matching evaluated chemotherapy benefit in completely resected patients. Results: The LightGBM model achieved the best discriminative performance (AUC = 0.834, 0.828, 0.800 for 1‐, 3‐, 5‐year OS) with excellent generalizability in external validation. SHAP analysis identified treatment modality as the top survival predictor; both surgery alone and surgery plus chemotherapy improved survival, but no significant OS difference was observed between the two strategies across all timepoints, consistent across subgroups (age, tumor size, etc.). Propensity‐score matching of 565 patients confirmed similar outcomes (median OS: 64 vs. 62 months; HR = 1.01, 95% CI: 0.82–1.20; p = 0.893). Conclusion: This study gives individualized survival estimates for stage IB LSCC, backing a risk‐adapted conservative adjuvant treatment approach. High‐risk subgroups got no extra benefit from postoperative chemotherapy, which may help integrate precision medicine and shared decision‐making in early‐stage LSCC management.

1 April 2026 in Science Progress
Verified
Journal Article
Open access
SMShanwu Ma
Shanwu Ma
CLChutong Lin
Chutong Lin
FGFuxin Guo
Fuxin Guo
YNYingze Ning
Yingze Ning
JTJizheng Tang
Jizheng Tang
GQGuangliang Qiang
Guangliang Qiang
Objective: Occupational exposure to carcinogens significantly contributes to the global burden of tracheal, bronchial, and lung (TBL) cancers. This study aims to quantify the global, regional, and national burden of TBL cancers attributable to occupational carcinogens using Global Burden of Disease (GBD) 2021 data and project trends to 2050. Additionally, we employ Mendelian Randomization (MR) to explore potential causal relationships between modifiable risk factors and TBL cancers. Methods: We extracted mortality and Disability-Adjusted Life Year (DALY) data for TBL cancers caused by occupational carcinogens from the GBD 2021 database. Exponential smoothing and autoregressive integrated moving average (ARIMA) models projected the burden to 2050. Two-sample MR analysis utilized genome-wide association study (GWAS) data, primarily from individuals of European ancestry, to investigate causal links. Results: In 2021, occupational carcinogens caused 285,628 deaths and 6.12 million DALYs globally. While age-standardized mortality and DALY rates declined in some high-income countries, low- and middle-income countries (LMICs) showed rising trends. Projections indicate a potential shift, with some regions plateauing while others face increasing burdens due to persistent exposure. MR analysis confirmed significant causal relationships, identifying higher BMI, smoking, visceral adiposity, and waist circumference as risk factors, while coffee consumption, dried fruit intake, physical activity, and education were protective. Conclusion: Despite progress, the burden of occupational TBL cancers remains substantial, particularly in LMICs. The discordance between declining rates in high-income nations and rising burdens elsewhere highlights the need for targeted interventions and stricter regulations. Integrating genetic evidence supports precision prevention strategies focusing on both occupational safety and modifiable lifestyle factors.